Cargando…

Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance

BACKGROUND: Doravirine has a unique resistance profile but how this profile might increase its usefulness beyond first-line therapy in persons with susceptible viruses has not been well studied. We sought to determine scenarios in which doravirine would retain activity against isolates from ART-naïv...

Descripción completa

Detalles Bibliográficos
Autores principales: Rhee, Soo-Yon, Schapiro, Jonathan M., Saladini, Francesco, Zazzi, Maurizio, Khoo, Saye, Shafer, Robert W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9903540/
https://www.ncbi.nlm.nih.gov/pubmed/36750835
http://dx.doi.org/10.1186/s12981-023-00503-5
_version_ 1784883492452040704
author Rhee, Soo-Yon
Schapiro, Jonathan M.
Saladini, Francesco
Zazzi, Maurizio
Khoo, Saye
Shafer, Robert W.
author_facet Rhee, Soo-Yon
Schapiro, Jonathan M.
Saladini, Francesco
Zazzi, Maurizio
Khoo, Saye
Shafer, Robert W.
author_sort Rhee, Soo-Yon
collection PubMed
description BACKGROUND: Doravirine has a unique resistance profile but how this profile might increase its usefulness beyond first-line therapy in persons with susceptible viruses has not been well studied. We sought to determine scenarios in which doravirine would retain activity against isolates from ART-naïve persons with transmitted drug resistance (TDR) and to identify gaps in available doravirine susceptibility data. METHODS: We analyzed published in vitro doravirine susceptibility data and applied the results to 42,535 RT sequences from ART-naïve persons published between 2017 and 2021. NNRTI drug resistance mutations (DRMs) were defined as those with a Stanford HIV Drug Resistance Database doravirine penalty score either alone or in combination with other mutations. RESULTS: V106A, Y188L, F227C/L, M230L, and Y318F were associated with the greatest reductions in doravirine susceptibility. However, several NNRTI DRMs and DRM combinations lacking these canonical resistance mutations had > tenfold reduced susceptibility including G190E, one isolate with G190S, three isolates with L100I + K103N, one isolate with K103N + P225H, and isolates with L100I + K103N + V108I and K101E + Y181C + G190A. Of the 42,535 ART-naïve sequences, 3,374 (7.9%) contained a NNRTI DRM of which 2,788 (82.6%) contained 1 DRM (n = 33 distinct mutations), 426 (12.6%) contained 2 DRMs (79 distinct pairs of mutations), and 143 (4.2%) contained ≥ 3 DRMs (86 distinct mutation patterns). Among the 2,788 sequences with one DRM, 112 (4.0%) were associated with ≥ 3.0-fold reduced doravirine susceptibility while 2,625 (94.2%) were associated with < 3.0-fold reduced susceptibility. Data were not available for individual NNRTI DRMs in 51 sequences (1.8%). Among the 426 sequences with two NNRTI DRMs, 180 (42.3%) were associated with ≥ 3.0 fold reduced doravirine susceptibility while just 32 (7.5%) had < 3.0 fold reduced susceptibility. Data were not available for 214 (50.2%) sequences containing two NNRTI DRMs. CONCLUSIONS: First-line therapy containing doravirine plus two NRTIs is expected to be effective in treating most persons with TDR as more than 80% of TDR sequences had a single NNRTI DRM and as more than 90% with a single DRM were expected to be susceptible to doravirine. However, caution is required for the use of doravirine in persons with more than one NNRTI DRM even if none of the DRMs are canonical doravirine-resistance mutations. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12981-023-00503-5.
format Online
Article
Text
id pubmed-9903540
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-99035402023-02-08 Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance Rhee, Soo-Yon Schapiro, Jonathan M. Saladini, Francesco Zazzi, Maurizio Khoo, Saye Shafer, Robert W. AIDS Res Ther Research BACKGROUND: Doravirine has a unique resistance profile but how this profile might increase its usefulness beyond first-line therapy in persons with susceptible viruses has not been well studied. We sought to determine scenarios in which doravirine would retain activity against isolates from ART-naïve persons with transmitted drug resistance (TDR) and to identify gaps in available doravirine susceptibility data. METHODS: We analyzed published in vitro doravirine susceptibility data and applied the results to 42,535 RT sequences from ART-naïve persons published between 2017 and 2021. NNRTI drug resistance mutations (DRMs) were defined as those with a Stanford HIV Drug Resistance Database doravirine penalty score either alone or in combination with other mutations. RESULTS: V106A, Y188L, F227C/L, M230L, and Y318F were associated with the greatest reductions in doravirine susceptibility. However, several NNRTI DRMs and DRM combinations lacking these canonical resistance mutations had > tenfold reduced susceptibility including G190E, one isolate with G190S, three isolates with L100I + K103N, one isolate with K103N + P225H, and isolates with L100I + K103N + V108I and K101E + Y181C + G190A. Of the 42,535 ART-naïve sequences, 3,374 (7.9%) contained a NNRTI DRM of which 2,788 (82.6%) contained 1 DRM (n = 33 distinct mutations), 426 (12.6%) contained 2 DRMs (79 distinct pairs of mutations), and 143 (4.2%) contained ≥ 3 DRMs (86 distinct mutation patterns). Among the 2,788 sequences with one DRM, 112 (4.0%) were associated with ≥ 3.0-fold reduced doravirine susceptibility while 2,625 (94.2%) were associated with < 3.0-fold reduced susceptibility. Data were not available for individual NNRTI DRMs in 51 sequences (1.8%). Among the 426 sequences with two NNRTI DRMs, 180 (42.3%) were associated with ≥ 3.0 fold reduced doravirine susceptibility while just 32 (7.5%) had < 3.0 fold reduced susceptibility. Data were not available for 214 (50.2%) sequences containing two NNRTI DRMs. CONCLUSIONS: First-line therapy containing doravirine plus two NRTIs is expected to be effective in treating most persons with TDR as more than 80% of TDR sequences had a single NNRTI DRM and as more than 90% with a single DRM were expected to be susceptible to doravirine. However, caution is required for the use of doravirine in persons with more than one NNRTI DRM even if none of the DRMs are canonical doravirine-resistance mutations. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12981-023-00503-5. BioMed Central 2023-02-07 /pmc/articles/PMC9903540/ /pubmed/36750835 http://dx.doi.org/10.1186/s12981-023-00503-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Rhee, Soo-Yon
Schapiro, Jonathan M.
Saladini, Francesco
Zazzi, Maurizio
Khoo, Saye
Shafer, Robert W.
Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance
title Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance
title_full Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance
title_fullStr Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance
title_full_unstemmed Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance
title_short Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance
title_sort potential role of doravirine for the treatment of hiv-1-infected persons with transmitted drug resistance
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9903540/
https://www.ncbi.nlm.nih.gov/pubmed/36750835
http://dx.doi.org/10.1186/s12981-023-00503-5
work_keys_str_mv AT rheesooyon potentialroleofdoravirineforthetreatmentofhiv1infectedpersonswithtransmitteddrugresistance
AT schapirojonathanm potentialroleofdoravirineforthetreatmentofhiv1infectedpersonswithtransmitteddrugresistance
AT saladinifrancesco potentialroleofdoravirineforthetreatmentofhiv1infectedpersonswithtransmitteddrugresistance
AT zazzimaurizio potentialroleofdoravirineforthetreatmentofhiv1infectedpersonswithtransmitteddrugresistance
AT khoosaye potentialroleofdoravirineforthetreatmentofhiv1infectedpersonswithtransmitteddrugresistance
AT shaferrobertw potentialroleofdoravirineforthetreatmentofhiv1infectedpersonswithtransmitteddrugresistance